SCI Abstract

search
+
Beyond Proton Pump Inhibitors: Evaluating Treatment Strategies for Immune-Mediated Gastroenteritis from Cancer Immunotherapy
Beyond Proton Pump Inhibitors: Evaluating Treatment Strategies for Immune-Mediated Gastroenteritis from Cancer Immunotherapy
Immune-mediated gastroenteritis (IMG) has been commonly managed with proton pump inhibitors (PPIs), though their effective...
Translational Relevance of the Genomic Landscape of -Mutant Colorectal and Pancreatic Cancers
Translational Relevance of the Genomic Landscape of -Mutant Colorectal and Pancreatic Cancers
KRASG12D is one of the most prevalent driver mutations in patients with pancreatic ductal adenocarcinoma (PDAC) and colore...
Claudin-18.2 and Trop-2 as Emerging Biomarkers in Biliary Tract Cancers: Expression Analysis and Therapeutic Potential
Claudin-18.2 and Trop-2 as Emerging Biomarkers in Biliary Tract Cancers: Expression Analysis and Therapeutic Potential
Biliary tract cancers (BTCs), including cholangiocarcinoma and gallbladder carcinoma, are aggressive tumors with limited t...
CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis
CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis
Hormone receptor-positive/human epidermal growth factor receptor 2-positive (HR+/HER2+) breast cancer accounts for approxi...
Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What’s the Current Status?
Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What’s the Current Status?
The treatment of multiple myeloma has changed significantly in the last decade. Antibody-drug conjugates, T-cell immunothe...
Time-Dependent Comparative Effectiveness of First-Line Treatment for Metastatic Clear Cell Renal Cell Carcinoma: A Restricted Mean Survival Time-Based Network Meta-analysis
Time-Dependent Comparative Effectiveness of First-Line Treatment for Metastatic Clear Cell Renal Cell Carcinoma: A Restricted Mean Survival Time-Based Network Meta-analysis
Given that immune checkpoint inhibitor-based regimens frequently yield delayed separation and late plateaus, conventional ...
Current and Emerging Treatment Landscape of Common -Mutated Advanced Non-small Cell Lung Cancer
Current and Emerging Treatment Landscape of Common -Mutated Advanced Non-small Cell Lung Cancer
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been standard of ca...
Bispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges
Bispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges
Breast cancer remains a leading cause of cancer-related mortality despite advances in targeted therapies and immune checkp...
Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma
Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma
Multiple myeloma (MM) is a heterogeneous cancer that remains incurable. After treatment, the presence of residual myeloma ...
Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer
Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer
Advanced ovarian cancer carries a poor prognosis despite standard surgery and chemotherapy. Although poly (ADP-ribose) pol...
Concordance Analysis of Microsatellite Instability via NGS and Mismatch Repair Deficiency via IHC in Endometrial and Colorectal Cancer
Concordance Analysis of Microsatellite Instability via NGS and Mismatch Repair Deficiency via IHC in Endometrial and Colorectal Cancer
Assessment of mismatch repair (MMR) function provides critical guidance for diagnosis, prognosis, and therapeutic decision...
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab
Currently, data concerning the prognostic impact of metastatic sites in biliary tract cancers (BTC) are limited. The aim o...
Durvalumab: A Review in Limited-Stage Small Cell Lung Cancer
Durvalumab: A Review in Limited-Stage Small Cell Lung Cancer
Durvalumab (Imfinzi®) is a monoclonal antibody directed against programmed cell death-ligand 1 (PD-L1) and the ...
First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies
First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies
KPT-9274, a potentially first-in-class, dual NAMPT/PAK4 inhibitor, has shown single-agent anticancer activity in hematolog...
Copy Number-Based Oncogene Dominance May Suggest Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer
Copy Number-Based Oncogene Dominance May Suggest Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer
While oncogene co-amplification is frequently observed, its clinical significance remains unclear, particularly with regar...
Elranatamab Versus Teclistamab in Relapsed and Refractory Multiple Myeloma: A Real-World Propensity Score-Matched Study
Elranatamab Versus Teclistamab in Relapsed and Refractory Multiple Myeloma: A Real-World Propensity Score-Matched Study
Relapsed and refractory multiple myeloma treatment is challenging. Bispecific antibodies targeting B-cell maturation antig...
Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study
Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study
The optimal treatment strategy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NS...
Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics
Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics
Teclistamab is a B cell maturation antigen × CD3 bispecific antibody approved for relapsed/refractory multip...
Correction to: Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis
Correction to: Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International ...
Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors
Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors
Malignant pleural mesothelioma (MPM) is a rare and challenging cancer associated with asbestos fiber exposure, which offer...
A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis
A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis
Little is known regarding the prognostication of the Pan-Immune-Inflammation Value (PIV) in patients with recurre...
Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer
Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International ...
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis
PARP inhibitors (PARPis) are effective treatment options for patients with metastatic castration-resistant prostate cancer...
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)
Although ALK-translocated (ALK+) advanced non-small cell lung cancers (aNSCLCs) are currently treated with second- or thir...
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
Treatment options for metastatic renal cell carcinoma (mRCC) are rapidly expanding, and immunotherapy using checkpoint inh...
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Chapter 12 Daniel Costa: [11:38], the sentence“So, as an example, for these three cla...
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
Immune checkpoint inhibitor (ICI) monotherapy and ICI plus chemotherapy are approved first-line treatments for patients wi...
Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers
Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers
Chemo-immunotherapy (CIT) is the standard of care for advanced non-small cell lung cancer (NSCLC), but the impact of routi...
Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer
Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer
Delta-like ligand 3 (DLL3), a member of the Notch pathway, has been identified as a potential therapeutic target as it is ...
Durvalumab: A Review in Advanced Biliary Tract Cancer
Durvalumab: A Review in Advanced Biliary Tract Cancer
Durvalumab (Imfinzi®), a therapeutic human monoclonal antibody which binds to and blocks the activity of the immunosu...
Load More
format_indent_increase